Dana Hu-Lowe

基本信息

Career Trajectory

Bio

Dana Hu-Lowe, Ph.D., is the VP of Global Product Team Leadership of Adagene. Dr. Hu-Lowe has more than 20 years of experience in oncology drug discovery, pharmacology, translational research, and clinical development, with over seven years of experience in project and strategic alliance management, and leadership of both preclinical and clinical product programs.

Research Interests

Papers共 64 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

578P Increased Therapeutic Index of Muzastotug (ADG126), a Masked Anti-Ctla-4 Antibody, in Combination with Pembrolizumab (pembro) Enables Significant Clinical Benefits and Supports Further Clinical Development in Patients with Metastatic MSS CRC

D. Li, S.Y. Kim, H.K. Kim, S. Sharma,S.J. Shin, J. Lee, S-A. Im, X.K. She, Y. Li, L.E.C. Chung, P. Xiao, G. Liu, S. Zeng,D. HuLowe,M. Chisamore,P.P. Luo,J. Zha, M.R. Patel

Annals of Oncology (2024): S468-S469

Cited0Views0Bibtex

Supplementary Figures 1-3 from HGF/c-Met Acts As an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

Farbod Shojaei,Joseph H. Lee,Brett H. Simmons,Anthony Wong,Carlos O. Esparza,Pamela A. Plumlee,Junli Feng,Albert E. Stewart,Dana D. Hu-Lowe,James G. Christensen

crossref（2023）

Cited0Views0Bibtex

Supplementary Figure 2 from Dual Functional Monoclonal Antibody PF-04605412 Targets Integrin Α5β1 and Elicits Potent Antibody-Dependent Cellular Cytotoxicity

Gang Li,Lianglin Zhang,Enhong Chen,Jianying Wang,Xin Jiang,Jeffrey H. Chen,Grant Wickman,Karin Amundson,Simon Bergqvist,James Zobel,Dana Buckman,Sangita M. Baxi,Steven L. Bender,Gerald F. Casperson,Dana D. Hu-Lowe

crossref（2023）

Cited0Views0Bibtex

Supplementary Figure 3 from Cellular Source and Amount of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Tumors Determine Response to Angiogenesis Inhibitors

Barbara Sennino,Frank Kuhnert,Sebastien P. Tabruyn,Michael R. Mancuso,Dana D. Hu-Lowe,Calvin J. Kuo,Donald M. McDonald

crossref（2023）

Cited0Views0Bibtex

Supplementary Figures S1-S7 from Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

Dana D. Hu-Lowe,Helen Y. Zou,Maren L. Grazzini, Max E. Hallin,Grant R. Wickman,Karin Amundson,Jeffrey H. Chen, David A. Rewolinski, Shinji Yamazaki,Ellen Y. Wu,Michele A. McTigue,Brion W. Murray,Robert S. Kania, Patrick O'Connor,David R. Shalinsky, Steve L. Bender

openalex（2023）

Cited0Views0Bibtex

Supplementary Figure 2 from Cellular Source and Amount of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Tumors Determine Response to Angiogenesis Inhibitors

Barbara Sennino,Frank Kuhnert,Sebastien P. Tabruyn,Michael R. Mancuso,Dana D. Hu-Lowe,Calvin J. Kuo,Donald M. McDonald

crossref（2023）

Cited0Views0Bibtex

Supplementary Methods, Figure Legends 1-5 from Dual Functional Monoclonal Antibody PF-04605412 Targets Integrin Α5β1 and Elicits Potent Antibody-Dependent Cellular Cytotoxicity

openalex（2023）

Cited0Views0Bibtex

Supplementary Methods, Figure Legends 1-3 from Cellular Source and Amount of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Tumors Determine Response to Angiogenesis Inhibitors

Barbara Sennino,Frank Kuhnert,Sebastien P. Tabruyn,Michael R. Mancuso,Dana D. Hu-Lowe,Calvin J. Kuo,Donald M. McDonald

crossref（2023）

Cited0Views0Bibtex

Abstract CT233: Initial Results of a Phase 1b/2 Study of ADG126 (a Masked Anti-Ctla-4 SAFEbody®) in Combination with Pembrolizumab (an Anti-Pd-1 Antibody) in Patients with Advanced/metastatic Solid Tumors

Daneng Li,Sunil Sharma,Kristine She,Wenda Li, Ai Li,Songmao Zheng,Guizhong Liu, Ogon Ndukwo,Dana Hu-Lowe,Michael Chisamore,Peter Luo,Jiping Zha,Manish R. Patel

Cancer Researchno. 8_Supplement (2023)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Vice President

Papers共 64 篇Author StatisticsCo-AuthorSimilar Experts